

**DRUG UTILIZATION REVIEW BOARD**  
**January 18, 2012**  
**615 Howerton Court, 2<sup>nd</sup> floor, Jefferson City, MO 65109**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, PharmD  
Stacy Mangum, PharmD  
Sandra Bollinger, PharmD  
Kenneth Haller, MD  
Glenn Talboy, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD

**DUR BOARD MEMBERS ABSENT**

Jennifer Passanise, ANCC-BC, FNP  
Charlene Heyde, RPh  
Kirk Nelson, MD

**MHD STAFF PRESENT**

Rhonda Driver, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Tasia Roberts, Administrative Assistant  
Whitney Maloy, Sr. Office Support Assistant  
Ashley Wilson, DUR Coordinator  
Andrew Haslag, Fiscal Manager  
Marga Hoelscher, Deputy Director  
Angela Wilson, Pharmacy Unit Supervisor  
Allison Lauf, RN  
Mary Heet, RN  
Jenna Twehus, RN  
Jayne Zemmer, Program Manager

**CONTRACTED STAFF PRESENT**

Jennifer Kemp-Cornelius, PharmD, ACS Healthcare  
Josh Moore, Clinical Pharmacist, ACS Heritage  
Katie Wilbers, Clinical Pharmacist, ACS  
Geri Roling, RN, Wipro (Formerly Infocrossing Healthcare)  
Annette Walther, Wipro (Formerly Infocrossing Healthcare)

**OTHERS IN ATTENDANCE**

Jim Baumann, Pfizer  
Suzanne Goot, Abbott  
Jared Lurk, Novartis

Bruce Song, AstraZeneca  
Mike Kloos, Pfizer  
Sam Smothers, MedImmune

Lon Lowery, Novartis  
Dave Sproat, BMS

Hank Lavellet, Forest  
Eric Blake, Merck

\*Many names on the sign in sheet were illegible. Sign in sheet on file for review.

<b>Welcome, Introductions and Opening Remarks</b>	Acting Chairman, Susan Abdel-Rahman, PharmD, called the meeting to order at approximately 10:10 a.m. A quorum was established. Rhonda Driver, RPh, Director of Pharmacy, facilitated the meeting on behalf of the MO HealthNet Division (MHD). All MO HealthNet, DUR Board members, and contracted staff introduced themselves for the new attendees. Ms. Driver announced that future meeting locations are unknown and to keep checking the Calendar of Events on the website.
<b>Minutes Approval</b>	Minutes of the October 2011 meeting were reviewed and approved as submitted.
<b>Pharmacy Program/Budget Update</b>	Marga Hoelscher, Deputy Director, discussed the Governor's Division recommendations for MO HealthNet during the State of the State. The budget has booked some savings on generics that should go generic this year. Ms. Hoelscher stated MO Healthnet is in good shape for now. Andrew Haslag, Fiscal Manager, added that the generic savings budget is a fairly large number. MO Healthnet will want to make sure we are doing what we need to do to keep this savings in place. No other changes have been submitted. Jayne Zemmer, Program Manager, addressed the Health Home Initiative that came through the Affordable Care Act. Ms. Zemmer spoke on the qualifiers that would need to be in place in order for a provider to participate. There will be two programs: Community Mental Health Center Health Homes, which DMH will spearhead which started December 2011; and Primary Care Health Homes which the State Plan Amendment was just approved in December.
<b>Review of Prior Authorization Meeting:</b>	Copies of the agenda and draft minutes, including public hearing, from the December 15, 2011 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
<b>Implementation Schedule</b>	An updated copy of the <i>Proposed Implementation Schedule for Edits</i> , including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings which included and annual PDL implementation. This schedule may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Drug Review</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> - Drug monographs were available for review at <a href="http://www.heritage-info.com/mocaidrx">http://www.heritage-info.com/mocaidrx</a> for all new products reviewed this quarter (Identified by First Data Bank in July, August, and September 2011). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Ms. Driver reviewed the MHD recommendations for products whose review was completed this quarter.</li> <li>• <b>Decision</b> – In the interest of time the Board agreed to block these and the Preferred Drug List (PDL) recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote and approved as submitted. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL)</b>	Products and classes under review this quarter have existing contracts through December 31, 2011. Recommended changes to the edits were bolded for easy identification.

<b>Vivitrol Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting additions to the criteria originally recommended by the Department of Mental Health, including which provider types are able to prescribe the product and clarification on what constitutes an adequate trial of oral naltrexone.</li> <li>• <b>Decision</b> – In the interest of time the Board agreed to block recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This PDL recommendation was accepted and added to the block vote. (See Roll Call Vote)</li> </ul>
<b>SNRI Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting additions to the approval diagnoses to include Osteoarthritis and Lumbago.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Zostavax Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting the age range for therapy is now 50 years and older.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Amitiza Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting the addition of chronic idiopathic constipation to the approval diagnoses.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Ampyra Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the existing criteria document. There were no edit change recommendations from MHD. Manufacturer requested annual review.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Tetracyclines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. The Drug Prior Authorization Committee recommended allowing Demeclocycline for SIADH treatment; will be added to this criteria.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Topical Steroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting the list was voluminous and difficult to sort through.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>NSAIDs</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Cough &amp; Cold Preparations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting this too was a list that was voluminous and difficult to sort through.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>ACS Healthcare Update</b>	Jennifer Kemp-Cornelius, PharmD reviewed the regression analysis reports for the <i>Atypical Antipsychotic Edit, ADHD Edit, SSRI Edit and SNRI edit</i> . Discussion ensued surrounding how these analysis' could be extrapolated to fiscal savings that could be attributed to the implementation of the edits. ACS and MHD will continue to refine the analysis reports in order to quantify cost avoidance due to these edits. An additional discussion ensued regarding the upcoming implementation of the <i>Short Acting Narcotic Edits</i> . Ms. Driver and Ms. Kemp-Cornelius reported that the edits will be implemented soon. ACS and MHD wanted to be certain that the algorithms were written in a way that would curb inappropriate use of short acting narcotic agents without denying access to care for those patients with legitimate acute pain issues. Members agreed that a way to allow a small quantity of medication in certain circumstances to allow the primary physician time to obtain a PA if needed was an appropriate course of action.
<b>Preferred Drug List Discussion/Therapeutic Classes</b>	A handout of therapeutic categories to be considered for inclusion on the PDL for the next quarter and meeting was provided in the meeting packet and to all attendees. These categories will be an annual review of products with contracts expiring December 31, 2011. The Division will also post these classes to the Web page.
<b>Top 25 Drugs by Cost</b>	No changes were available for this meeting.
<b>Call Center Statistics</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics for November 2011 were included. Cyber Access Active User Counts and Logging Information reports detailing activity through December 2011 were shared.
<b>Program Utilization Information/Other Business</b>	During the next few months the Department and Division plan to work to fill the various vacancies on the Division's advisory groups including this Committee and the Drug PA Board. Future meetings will be held at the James C. Kirkpatrick State Information Center, located at 600 West Main Street, Jefferson City, Missouri.
<b>Adjourn</b>	The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote). The next meeting is scheduled for April 18, 2012.

### Roll Call Votes – January 18, 2012

<b>Member</b>	<b>Meeting Minutes</b>	<b>All Recommendations Block Vote</b>	<b>Closed Session</b>	<b>Adjourn</b>
Susan Abdel-Rahman	Yeah	Yeah	<b>Motion</b>	Yeah
Charlene Heyde	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>
Sandra Bollinger	<b>Motion</b>	<b>Second</b>	<b>Second</b>	<b>Motion</b>
Kenneth Haller	<i>Absent</i>	Yeah	Yeah	Yeah
Glenn Talboy	<b>Second</b>	Yeah	Yeah	<b>Second</b>
Jennifer Passanise	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>
Stacy Mangum	Yeah	<b>Motion</b>	Yeah	Yeah
Kirk Nelson	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>	<i>Absent</i>
Ginger Nicol	Yeah	Yeah	Yeah	Yeah
Randy Beckner	Yeah	Yeah	Yeah	Yeah

**EXECUTIVE SESSION**

January 18, 2012

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, PharmD  
Stacy Mangum, PharmD  
Sandra Bollinger, PharmD  
Kenneth Haller, MD  
Glenn Talboy, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD

**DUR BOARD MEMBERS ABSENT**

Jennifer Passanise, ANCC-BC, FNP  
Charlene Heyde, RPh  
Kirk Nelson, MD

**MHD STAFF PRESENT**

Rhonda Driver, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Tasia Roberts, Administrative Assistant  
Whitney Maloy, Sr. Office Support Assistant  
Ashley Wilson, DUR Coordinator  
Andrew Haslag, Fiscal Manager  
Marga Hoelscher, Deputy Division Director  
Angela Wilson, Pharmacy Unit Supervisor  
Allison Lauf, RN  
Mary Heet, RN  
Jenna Twehus, RN

**CONTRACTED STAFF PRESENT**

Jennifer Kemp-Cornelius, PharmD, ACS Healthcare  
Josh Moore, Clinical Pharmacist, ACS Heritage  
Katie Wilbers, ACS  
Geri Roling, RN, Wipro (Formerly Infocrossing Healthcare)  
Annette Walther, Wipro (Formerly Infocrossing Healthcare)

Minutes Review	Minutes of the July Executive Session were approved as submitted
Case Reviews	Jenna Twehus, RN presented two handouts that detailed provider summary results and benchmark data for patients being prescribed large amounts of narcotics. The discussion included why these 2 patients were being prescribed high dosages and multiple narcotics. The board decided to do further research to get more information on these issues. No other issues were discussed.
Adjourn	Executive session adjourned at approximately 1:30p.m. (See roll call vote)